Day One Biopharmaceuticals, Inc.
DAWN
$21.31
$0.020.09%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.60% | 31.11% | 2,190.50% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.60% | 31.11% | 2,190.50% | -- | -- |
| Cost of Revenue | 226.01% | 514.32% | 1,487.13% | -- | -- |
| Gross Profit | 11.99% | 19.97% | 2,256.94% | -- | -- |
| SG&A Expenses | 4.45% | 7.69% | 20.39% | 40.61% | 52.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.74% | -2.95% | 1.24% | 59.25% | 66.66% |
| Operating Income | 39.82% | 19.78% | 61.14% | 13.70% | -3.01% |
| Income Before Tax | -23.71% | -73.74% | 46.12% | 70.36% | 53.23% |
| Income Tax Expenses | -127.66% | 866.27% | 260.31% | -- | -- |
| Earnings from Continuing Operations | -12.38% | -80.04% | 43.28% | 66.94% | 49.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.38% | -80.04% | 43.28% | 66.94% | 49.45% |
| EBIT | 39.82% | 19.78% | 61.14% | 13.70% | -3.01% |
| EBITDA | 41.02% | 20.97% | 62.11% | 14.74% | -2.27% |
| EPS Basic | 0.24% | -44.69% | 53.48% | 73.65% | 56.61% |
| Normalized Basic EPS | 7.08% | -48.13% | 54.51% | 75.98% | 62.08% |
| EPS Diluted | 0.58% | -43.98% | 53.42% | 73.56% | 56.56% |
| Normalized Diluted EPS | 7.21% | -47.93% | 54.44% | 75.93% | 62.02% |
| Average Basic Shares Outstanding | -17.09% | 15.47% | 17.08% | 16.56% | 16.91% |
| Average Diluted Shares Outstanding | 10.55% | 15.36% | 17.17% | 16.66% | 17.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |